HomeOpen Access NewsClinical Trials

Clinical Trials

Early dog exposure may reduce childhood eczema risk

Having a pet dog may lower the risk of eczema in children who are genetically prone to the condition, shedding light on how environmental factors may influence genetic risks.

Polymers and polymer-based drug delivery in the treatment of dry eye disease

Professor Heather Sheardown, C20/20 Ophthalmic Materials Innovation Hub, Department of Chemical Engineering, McMaster University, explores how polymers can be used to treat dry eye disease.

European Medicines Agency say AstraZeneca does not cause blood clots

The safety committee of the European Medicines Agency said the investigation did not prove that AstraZeneca vaccinations cause blood clots - describing the possibility as an "extremely small likelihood".

COVID-19: The evolution of testing & sequencing

Novacyt Group, discusses the evolution of testing and sequencing during COVID-19 with a panel of distinguished speakers.

Birth control creates higher risk of blood clots than AstraZeneca vaccine

Currently, several EU countries are suspending use of the AstraZeneca vaccine due to reports of blood clot risks - in response, people are speaking out about the higher risk of blood clots posed by contraceptive pills used globally.

European Medicines Agency says AstraZeneca vaccine still safe to use

Over the weekend, the Republic of Ireland suspended their use of AstraZeneca due to reports of blood clots in Norway - in response, the European Medicines Agency (EMA) says the AstraZeneca vaccine is still safe to use.

Novavax 96.4% effective against the original COVID mutation

The US based vaccine appears to be 96.4% effective against the original COVID mutation, with 86% efficacy against the UK variant and only 55% against the South African variant.

Bharat Biotech COVID vaccine shows 81% efficacy at Phase Three

The Bharat Biotech COVID vaccine, COVAXIN, appears to be 81% efficient against the virus in Phase Three of clinical trials.

COVID vaccines for mutations will be given faster approval in the UK

Medical regulators will fast-track COVID vaccines for mutations, similar to how seasonal flu shots are developed and released.

The AstraZeneca vaccine is atleast 60% effective for people aged 70 and over

A study examining older people in the UK found that only one dose of the AstraZeneca vaccine is atleast 60% effective for people aged 70 and over.

Israel will now vaccinate Palestinians who have permits to work 

Israel faced international criticism on their refusal to vaccine Palestinians - now, the country will begin rolling out Pfizer shots to some Palestinians who have work permits.

FDA approves the Johnson & Johnson vaccine for use

The US Food and Drug Administration (FDA) approved the Johnson & Johnson vaccine, with an efficacy of 86%, as the next to be rolled out across the US.

The Pfizer vaccine is stopping 92% of severe COVID cases in Israel

Israel is currently leading the world in COVID vaccination, with real-world data to suggest that the Pfizer vaccine is working to stop 92% of severe COVID cases.

REACT study: UK vaccine hesitancy is the highest in London

New data from the REACT study finds that 14% of the UK population have antibodies against COVID-19 now, but that vaccine hesitancy is currently highest in London.

The Californian COVID mutation is more infectious

The Californian COVID mutation appears to be as infectious as the UK or South African mutations - but does it have the potential to be more deadly?

FDA reveals that Johnson & Johnson vaccine is 86% effective

New documents from the FDA show that the Johnson & Johnson vaccine appears to be 86% effective against COVID-19 - signalling that it will soon be approved in the US.

Pfizer vaccine can reduce COVID hospitalisation and death by 75%

Early stage data from the vaccine rollout in the UK appears to show that COVID hospitalisation and death are reduced by over 75% in people with the Pfizer vaccine.

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders